Kodiak Sciences Inc. (KOD) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Is Kodiak Sciences Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, Kodiak Sciences Inc. (KOD) trades at $98.89 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Kodiak Sciences Inc.
Market cap $6B · 52 weeks $17 – $100 (3 % below the high) · P/E no earnings · Dividend none · Next earnings November 12, 2026 · expected EPS -$1.06 · Closing price, Nov 3 · accounts published Aug 12.
- Valuation: P/E — (no earnings).
- Balance sheet: Altman Z −3.2 (fragile).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- Cash Runway 19 months, fails.
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 25.1×, fails.
- Total Debt 0.8×, passes.
- Annual cash burn $2.56, info.
Against its peers (reference peers) — Kodiak Sciences Inc.: P/E —; EV/EBITDA —; ROIC —; $6.2B. Regeneron Pharmaceuticals, Inc. (P/E 21.5×; EV/EBITDA 15.7×; ROIC 10.9 %; $100B), Bausch + Lomb Corporation (P/E —; EV/EBITDA 17.1×; ROIC 3.8 %; $7.2B), Ligand Pharmaceuticals Incorporated (P/E 140×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.3B).
Profitability
| Return on Equity | -273.23% |
| Return on Invested Capital | -115.23% |
| Return on Assets | -94.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 1.57 |
| Current Ratio | 2.49 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.23 |
Price Performance
| 1 month | +4.07% |
| 3 months | +115.04% |
| Year-to-date | +249.18% |
| 1 year | +439.39% |
| 3 years | +4036.86% |
| 5 years | +295.42% |
Related companies: REGN · BLTE · BLCO · VRTX · 0QZU.L · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of KOD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks